Database Query Results : , , ALK

ALK, anaplastic lymphoma receptor tyrosine kinase: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor protein-tyrosine kinase superfamily.
ALK inhibitors, has substantially improved outcomes for patients with ALK-positive NSCLC. The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib.

ALK is used as a clinical biomarker for Fusion targeted therapy
Scientific Papers found: Click to Expand⟱

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 0

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ALK, anaplastic lymphoma receptor tyrosine kinase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:8  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page